HONG KONG, CHINA and MONTREAL, QC--(Marketwired - January 03, 2018) - Angiochem Inc. and Xinogen (Hong Kong) Pharma Co. Ltd. ("Xinogen"), a wholly-owned subsidiary of Beijing Shenogen Pharma Group Ltd. entered a license and collaboration agreement to develop and commercialize ANG1005 in China for treatment of patients with leptomeningeal carcinomatosis from breast cancer. Xinogen was granted exclusive rights to develop and commercialize ANG1005 in the Greater China region. In return, Angiochem will receive upfront and milestone payments as well as a royalty based on future product sales.
Angiochem is currently developing ANG1005 for treatment of leptomeningeal carcinomatosis from breast cancer. The company's next clinical trial is due to start in 2018. "Angiochem is looking forward to collaborating with Xinogen," said John Huss, Executive Chairman of Angiochem. Dr. Kun Meng, CEO of Beijing Shenogen Pharma Group Ltd., also expressed his enthusiasm and confidence about collaborating with Angiochem.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.
About Beijing Shenogen Pharma Group Ltd.:
Beijing Shenogen Pharma Group is a drug discovery and development company founded in 2006 based in Beijing, China that dedicated the development of first-in-class therapeutics for cancer treatment. The Company possesses robust intellectual property rights around novel targets for anticancer therapies. Additional information is available at http://www.shenogen.com.
Jun Bao, PhD., MBA
Senior Vice President and Chief Business Officer